AGENUS INC (AGEN)
Health Care · NASDAQ
A clinical-stage immuno-oncology company advancing checkpoint immunotherapy and combination therapies, primarily botensilimab, while generating near-term revenue through royalty sales and partnerships.
What AGENUS INC does
Agenus Inc is a biopharmaceutical company focused on the development of immuno-oncology product candidates, with botensilimab as its lead therapeutic targeting cancer indications. The company is advancing combination therapy programs alongside its lead program and has expanded its revenue through non-cash royalty revenue from the sale of future royalties and milestones related to prior partnerships. Agenus maintains equity method investments in related entities and generates pre-commercial product revenue from early-stage commercialization efforts.
Themes: ["immuno-oncology / checkpoint inhibitors","cancer immunotherapy","clinical-stage therapeutics","combination therapies","Immuno-oncology / checkpoint inhibitors"]
Fundamentals
- Price$3.24 as of 2026-07-09 close
- Market cap$135M as of 2026-07-10
- 1-year return-37.5% as of 2026-07-09 close
- P/E2.09 as of 2026-07-10
- Net margin+52.2% as of 2026-07-10
- Gross margin+99.3% as of 2026-07-10
- ROE+76.6% as of 2026-07-10
- Debt / equity4.01 as of 2026-07-10
- Revenue growth (YoY)+24.5% as of 2026-07-10
- Revenue CAGR (3y)+5.2% SEC XBRL
- Beta1.53 as of 2026-07-10
Key risks (from latest filing)
["Going concern warning from auditors and historical net losses with continued losses anticipated, creating significant financial and operational risk.","Botensilimab and combination programs are highly dependent on successful clinical development; failure to advance these candidates or encounter adverse events could halt pipeline progression.","Limited resources create strain on ability to simultaneously advance multiple product candidates and successfully bring programs to regulatory approval and commercialization."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.